

PEER-REVIEW REPORT

Name of journal: *World Journal of Transplantation*

Manuscript NO: 78241

Title: Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06266268

Position: Peer Reviewer

Academic degree: PhD

Professional title: Chief Physician

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2022-06-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-06-16 08:20

Reviewer performed review: 2022-06-22 09:11

Review time: 6 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This review proposed that immunotherapy as a form of LRT prior to LT is a promising new approach that aims to downstage therapy and increase the number of patients receiving curative treatment. Further, this review summarized the role, safety profile, and future considerations regarding the use of neoadjuvant immunotherapy prior to LT in patients with HCC. The theme is interesting and appealing to readers. The content is reasonable, the structure is clear, and the language is appropriate and easy to understand.

PEER-REVIEW REPORT

Name of journal: *World Journal of Transplantation*

Manuscript NO: 78241

Title: Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06169813

Position: Peer Reviewer

Academic degree: PhD

Professional title: Senior Researcher

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2022-06-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-06-30 02:22

Reviewer performed review: 2022-06-30 02:45

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

In this review, the authors summarize the role, safety, and future considerations of neoadjuvant immunotherapy before LT in HCC patients. Case reports and clinical trials evaluating the safety and efficacy of neoadjuvant immunotherapy highlight important aspects of this newly developed approach to HCC management. The author has read and reviewed a great deal of material, including classic works and the most recent research findings in connected subjects. The author provided an overview of "the role of immunotherapy in reducing hepatocellular cancer prior to liver transplantation." I believe this to be a decent review. In addition, I have 2 suggestions that I hope the author can consider: 1. Immunotherapy for liver cancer patients generally requires specific dosage regimens, including drug doses and drug varieties, which may be one of the reasons why immunotherapy cannot be promoted on a large scale, especially in smaller hospitals. 2. Although liver transplantation is one of the treatments for liver cancer, the paucity of donors substantially limits the popularization of this treatment. Is it possible to do autologous liver transplantation following immunotherapy?